Structure Therapeutics (GPCR) maintains a Buy rating after its oral GLP-1 drug aleniglipron showed up to 16.2% weight loss in Phase 2b trials targeting obesity. The drug demonstrated a favorable safety profile and is now in Phase 3, with pivotal data expected by Q4 2028. GPCR's $1.34 billion cash reserve is sufficient to fund Phase 3 completion, supporting its development despite high R&D costs. Risks include competition and potential Phase 3 failure, but the drug's efficacy and cost advantages suggest blockbuster potential.
Chery Auto will showcase its purpose-built Level 4 (L4) Robotaxi at the 2026 Chery International User Summit and sign a strategic cooperation agreement with UAE-based K2. The Robotaxi offers a fully driverless passenger experience from booking to rid...
AiMOGA Robotics, a Chery brand, unveiled Mobo, its first consumer-grade humanoid robot designed for home companionship, at the 2026 Chery International User Summit. Powered by AiMOGA's proprietary AI system MoAgent, Mobo can interpret complex command...
AiMOGA Robotics, a Chery brand, unveiled Mobo, its first consumer humanoid robot designed for home companionship, at the 2026 Chery International User Summit. Mobo uses advanced AI to understand complex commands, navigate home environments, and remem...
AiMOGA Robotics, a Chery brand, will debut Mobo, its first consumer-grade humanoid robot designed as a home companion, at the 2026 Chery International User Summit in Wuhu, China. Mobo features advanced AI for understanding complex commands, spatial a...
AiMOGA Robotics, a brand under Chery, introduced Mobo, its first consumer-grade humanoid robot designed as a family companion, at the 2026 Chery International User Summit. Mobo operates with AiMOGA's proprietary MoAgent AI, enabling it to understand ...
